| Literature DB >> 27920754 |
Saba Noor1, Jamal Ahmad1, Iqbal Parwez2, Maaz Ozair1.
Abstract
The study was carried on diabetic foot patients to deduce clinical attributes, the occurrence of the range of aerobic microbial flora and to assess their comparative in vitro susceptibility to the customarily used antimicrobials. We also studied the potential risk factors involved in the development of non-healing ulcers. A total of 87 organisms were isolated from 70 specimens, including Escherichia coli (19.5%) among the Gram-negative and Staphylococcus aureus (18.4%) among the Gram-positive as the predominant aerobes explored. Pseudomonas aeruginosa and E. coli were predominant isolates of non-healing ulcers. The antimicrobial sensitivity pattern revealed that vancomycin (100%) and amikacin (90.4%) exhibited highest sensitivity to Gram-positive cocci, while all strains of P. aeruginosa were sensitive toward imipenem (100%). The prevalent uncontrolled glycemic status, altered lipid spectra, the existence of neuropathy, and peripheral vascular disease, suggested predisposition toward the development of non-healing lesions. The study has underlined the need for continuous surveillance of bacteria and their antimicrobial sensitivity blueprints to provide the basis for empirical therapy and to minimize the risk of complications. Further, stringent clinical evaluation, and medical history will help in revealing the risk of developing non-healing status in diabetic foot ulcers.Entities:
Keywords: Antibiogram; Diabetic foot infection; Multi-drug resistant organisms; Non-healing ulcers; Type 2 diabetes
Year: 2016 PMID: 27920754 PMCID: PMC5118448 DOI: 10.3389/fmicb.2016.01792
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Clinical and demographical variables of subjects with healing and non-healing ulcers.
| N | 27 | 43 | ||
| Male (%) | 22 (78.5%) | 29 (82.5%) | NS | |
| Age (yrs) | 50.2±10.8 | 55.9±11.6 | < | |
| Diabetes duration (yrs) | 7.6±5.5 | 7.4±5.1 | NS | |
| BMI (kg/m2) | 25.5±5.2 | 31.1±3.1 | < | |
| HbA1c (%) | 9.1±2.0 | 11±3.6 | < | |
| FPG (mg/dL) | 170±44.2 | 200.7±58.6 | < | |
| Se. Cr (mg/dL) | 1.4±0.8 | 1.2±0.5 | NS | |
| TC (mg/dL) | 164.2±22.4 | 170.2±29.43 | NS | |
| TAGs (mg/dL) | 148.3±38.9 | 183.1±54.8 | < | |
| HDL (mg/dL) | 47.6±10.1 | 39.4±6.6 | < | |
| LDL (mg/dL) | 71.6±11.3 | 78.0±6.1 | < | |
| <4 cm2 | 13 (48.1%) | 12 (27.9%) | < | |
| ≥4 cm2 | 14 (51.8%) | 31 (72%) | ||
| Ulcer duration (months) | 1.2±0.7 | 1.7±0.6 | < | |
| 1 | 1 (3.7%) | 2 (4.6%) | NS | |
| 2 | 11 (40.7%) | 13 (30.2%) | NS | |
| 3 | 5 (18.5%) | 12 (27.9%) | NS | |
| 4 | 8 (29.6%) | 16 (37.2%) | NS | |
| Hypertension | 11 (39.2%) | 18 (45.7%) | NS | |
| Retinopathy | 20 (71.4%) | 29 (77.1%) | NS | |
| Neuropathy | 16 (39%) | 12 (24.3%) | < | |
| Nephropathy | 24 (85.3%) | 32 (95.4%) | NS | |
| Peripheral vascular disease | 15 (53.5%) | 29 (78.3%) | < | |
| Osteomyelitis | 12 (35.7%) | 31 (78.3%) | < | |
| 8 (29.6%) | 25 (58.1%) | < | ||
| Minor | 8 (29.6%) | 22 (51.1%) | NS | |
| Major | 0 (0%) | 3 (6.9%) | ||
N, number of subjects; BMI, body mass index; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; Se. Cr, serum creatinine; TC, total cholesterol; TAG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein; NS, not significant.
The bold values denote the p value obtained after applying student t-test and Chi- square statistical analysis when when variables of healing ulcer group were compared with non-healing ulcer group.
Distribution of 87 isolates in healing and non-healing diabetic foot ulcers.
| 5 (5.7%) | 12 (13.8%) | |
| 5 (5.7%) | 11 (12.6%) | |
| 3 (3.4%) | 12 (13.8%) | |
| 9 (10.3%) | 4 (4.6%) | |
| 8 (9.2%) | 3 (3.4%) | |
| 5 (5.7%) | 5 (5.7%) | |
| 2 (2.3%) | 3 (3.4%) |
n, number of isolates.
Antibiogram of Gram-positive cocci.
| Amikacin | 14 (87.5%) | 2 (12.5%) | 5 (100%) | 0 (0%) | 19 (90.5%) | 2 (9.5%) |
| Erythromycin | 10 (62.5%) | 6 (37.5%) | 4 (80%) | 1 (20%) | 14 (66.7%) | 7 (33.3%) |
| Ciprofloxacin | 11 (68.75%) | 5 (31.25%) | 4 (80%) | 1 (20%) | 15 (71.4%) | 6 (28.6%) |
| Gentamicin | 10 (62.5%) | 6 (37.5%) | 4 (80%) | 1 (20%) | 14 (66.7%) | 7 (33.3%) |
| Levofloxacin | 6 (37.5%) | 10 (62.5%) | 4 (80%) | 1 (20%) | 10 (47.6%) | 11 (52.4%) |
| Oxacillin | 11 (68.75%) | 5 (31.25%) | 5 (100%) | 0 (0%) | 16 (76.2%) | 5 (23.8%) |
| Vancomycin | 16 (100%) | 0 (0%) | 5 (100%) | 0 (0%) | 21 (100%) | 0 (0%) |
S, sensitive; R, resistant; n, number of isolates.
Antibiogram of Enterobacteriace.
| Amikacin | 13 (76.5%) | 4 (23.5%) | 9 (69.2%) | 4 (30.8%) | 5 (45.4%) | 6 (54.5%) | 3 (30%) | 7 (70%) | 30 (58.8%) | 21 (41.2%) |
| Cefoperazone | 3 (17.6%) | 14 (82.35%) | 4 (30.8%) | 9 (69.2%) | 2 (18.2%) | 9 (81.8%) | 3 (30%) | 7 (70%) | 15 (29.4%) | 22 (43.1%) |
| Cefixime | 6 (35.3%) | 11 (64.7%) | 2 (15.4%) | 11 (84.6%) | 10 (90.9%) | 1 (9.0%) | 6 (60%) | 4 (40%) | 24 (47.0%) | 27 (52.9%) |
| Cefepime | 6 (35.3%) | 11 (64.7%) | 10 (76.9%) | 3 (23.1%) | 4 (36.4%) | 7 (63.6%) | 5 (50%) | 5 (50%) | 25 (49.0%) | 26 (51.0%) |
| Cefetriaxone | 6 (35.3%) | 11 (64.7%) | 10 (76.9%) | 3 (23.1%) | 2 (18.2%) | 9 (81.8%) | 4 (40%) | 6 (60%) | 22 (43.1%) | 29 (56.9%) |
| Gentamicin | 5 (29.4%) | 12 (70.6%) | 6 (46.15%) | 7 (53.8%) | 4 (36.4%) | 7 (63.6%) | 4 (40%) | 6 (60%) | 19 (37.2%) | 32 (62.7%) |
| Levofloxacin | 5 (29.4%) | 12 (70.6%) | 10 (76.9%) | 3 (23.1%) | 6 (54.5%) | 5 (45.4%) | 4 (40%) | 6 (60%) | 25 (49.0%) | 26 (51.0%) |
| Tobramycin | 5 (29.4%) | 12 (70.6%) | 6 (46.15%) | 7 (53.8%) | 6 (54.5%) | 5 (45.4%) | 3 (30%) | 7 (70%) | 20 (39.2%) | 30 (58.8%) |
| Cefeperazone + Sulbactam | 8 (47.0%) | 9 (52.9%) | 12 (92.3%) | 1 (7.7%) | 5 (45.4%) | 6 (54.5%) | 6 (60%) | 4 (40%) | 31 (60.8%) | 20 (39.2%) |
S, sensitive; R, resistant; n, number of isolates.
Antibiogram of .
| Amikacin | 5 (33.3%) | 10 (66.7%) |
| Ceftazidime | 4 (26.7%) | 11 (73.3%) |
| Cefepime | 4 (26.7%) | 11 (73.3%) |
| Levofloxacin | 6 (40.0%) | 9 (60.0%) |
| Sparfloxacin | 4 (26.7%) | 11 (73.3%) |
| Tobramycin | 5 (33.3%) | 10 (66.7%) |
| Piperacillin | 8 (53.3%) | 7 (46.7%) |
| Piperacillin + Tazobactam | 12 (80.0%) | 3 (20.0%) |
| Imipenem | 15 (100%) | 0 (0%) |
S, sensitive; R, resistant; n, number of isolates.